| 词条 | Ruplizumab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 464384589 | type = mab | mab_type = mab | source = zu/o | target = CD154 | tradename = Antova | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 220651-94-5 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | chemical_formula = | molecular_weight = }}Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2] References1. ^{{cite journal|pmid=15046525|year=2004|last1=Liossis|first1=SN|last2=Sfikakis|title=Costimulation blockade in the treatment of rheumatic diseases|volume=18|issue=2|pages=95–102|journal=BioDrugs|first2=PP|doi=10.2165/00063030-200418020-00003}} {{immunosuppressants}}{{Monoclonals for immune system}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{cite journal|doi=10.1093/rheumatology/kei118|pmid=16188945|year=2006|last1=Nakamura|first1=M|last2=Tanaka|first2=Y|last3=Satoh|first3=T|last4=Kawai|first4=M|last5=Hirakata|first5=M|last6=Kaburaki|first6=J|last7=Kawakami|first7=Y|last8=Ikeda|first8=Y|last9=Kuwana|first9=M|title=Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism|volume=45|issue=2|pages=150–6|journal=Rheumatology (Oxford, England)}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。